

COMMONWEALTH OF MASSACHUSETTS  
Board of Registration in Pharmacy

NOTICE OF THE REGULARLY SCHEDULED MEETING OF THE  
BOARD OF REGISTRATION IN PHARMACY

December 17, 2021

**Webex Information**

The regular session is open to the public by video or phone.

**For video access click on the following link:**

<https://statema.webex.com/statema/onstage/g.php?MTID=e3d906f6fbfd188016e983943fb8df86f>

**To access the meeting by phone:**

Call in Number: 1-203-607-0564 or toll free 1-866-692-3580

Access Code: 2420 129 6929

Attendee: #

*If you need reasonable accommodations in order to participate in the meeting, contact the DPH ADA Coordinator [Yulanda Kiner](#), Phone: 617-624-5848 in advance of the meeting. While the Board will do its best to accommodate you, certain accommodations may require distinctive requests or the hiring of outside contractors and may not be available if requested immediately before the meeting.*

**Agenda**

Time	#	Item	Page	Contact
8:00	I	CALL TO ORDER		J. Lanza
	II	APPROVAL OF AGENDA		
8:05	III	APPROVAL OF BOARD MINUTES <ul style="list-style-type: none"><li>Draft of December 3, 2021 Regular Session Minutes</li></ul>		

8:15	IV	<b>FLEX</b> <ul style="list-style-type: none"> <li>• Pharmacy issues related to Covid-19 and the state of emergency</li> <li>• Introduction of Rita Morrelli</li> <li>• A word of thanks to Andrew Stein</li> <li>• Comments to USP regarding proposed revisions to general chapters &lt;795&gt; and &lt;797&gt;</li> <li>• Election of Board Officers</li> </ul>		
8:35	V	<b>APPLICATIONS</b> <ul style="list-style-type: none"> <li>• Freedom Fertility Pharmacy; DS89717 – Waivers</li> </ul>		
8:40	VI	<b>POLICIES</b> <ul style="list-style-type: none"> <li>• CriticalPoint courses for sterile compounding CE</li> </ul>		
8:45	VII	<b>PETITION FOR WAIVER 247 CMR 3.01(7)</b> <i>(7) An applicant who fails either NAPLEX or MPJE must reapply to sit for the examination which the applicant failed within one year of the administration date of the original examination in order for both examination scores to be considered together. If the applicant does not pass both NAPLEX and MPJE within this one year period, the applicant must apply to retake both NAPLEX and MPJE.</i> <ul style="list-style-type: none"> <li>• Nnenna M. Ireghu, PI162678</li> </ul>		
9:00	VIII	<b>PTT LICENSE EXTENSION REQUEST</b>  <u>PTT04818 Mann, Penny (CVS)</u> Issue Date: 04/23/2019 Expiration Date: 04/23/2020 20 hours  <u>PTT05976 Delea, Daniel N (CVS)</u> Issue Date: 08/13/2019 Expiration Date: 08/13/2020 180 hours  <u>PTT08466 Colston, Sarah (CVS)</u> Issue Date: 06/18/2020 Expiration Date: 06/18/2021 144 hours		

9:15	IX	<b>FILE REVIEW</b>					
		1	CAS-2021-0979	SA-INV-18620			Onyeijen Mgbejume, PH237291
		2	CAS-2012-0777	PHA-2021-0074			CVS #166, DS3449
		3	CAS-2021-0778	PHA-2021-0075			CVS #657, DS89715
		4	CAS-2021-0652	PHA-2021-0055			CVS #1803, DS8988
		5	CAS-2021-0590	PHA-2021--0048			CVS #365, DS3452
		6	CAS-2021-0592	PHA-2021-0046	CVS #2566, DS3086		
9:45	X	<b>EXECUTIVE SESSION</b> The Board will meet in Executive Session as authorized pursuant to M.G.L. c. 30A, § 21(a)(1) for the purpose of discussing the reputation, character, physical condition, or mental health, rather than professional competence, of an individual, or to discuss the discipline or dismissal of, or complaints or charges brought against, a public officer, employee, staff member or individual. Specifically, to evaluate the Good Moral Character as required for registration for a pending applicant and to review a request by a pharmacy intern for an extension of their license.				CLOSED SESSION	
10:20	XI	<b>M.G.L. c. 112, § 65C SESSION</b>				CLOSED SESSION	
11:00	XII	<b>ADJOURNMENT</b>					

**COMMONWEALTH OF MASSACHUSETTS  
BOARD OF REGISTRATION IN PHARMACY**

**MINUTES OF THE GENERAL SESSION**

**Via Remote WebEx Meeting**

**December 17, 2021**

---

**Board Members Present**

Julie Lanza, CPhT, President

Carly Jean-Francois, RN, NP Secretary

Sebastian Hamilton, Pharm D, MBA, RPh President-Elect

Susan Cornacchio, JD, RN (leaves meeting 10:07 AM)

Jennifer Chin, RPh

John Rocchio, RPh, PharmD (leaves meeting 10:07 AM)

Dr. Richard Lopez, MD

Caryn Belisle, RPh, MBA (arrives at 8:50 AM)

Sami Ahmed, Pharm.D., RPh, BCPS, BCSCP

Katie Thornell, RPh, MBA

Dawn Perry, JD

Delilah Barnes, RPh (Votes prior to 8:45 AM do not include D. Barnes due to audio problems which were resolved at 8:45 AM)

Rita Morelli, PharmD, BCACP, RPh

**Board Members Not Present**

**Board Staff Present**

David Sencabaugh, RPh, Executive Director

Monica Botto, CPhT, Assistant Executive Director

Heather Engman, JD, Board Counsel

William Frisch, RPh Director of Pharmacy Compliance

Michelle Chan, RPh, Quality Assurance Pharmacist

Richard Harris, Program Analyst

Joanna Chow, Office Support Specialist

Taylor Lee, Office Support Specialist

Joanne Trifone, RPh, Director of Investigations (leaves meeting at 10:20 AM)

Christina Moggi, RPh, Investigator

Julienne Tran, PharmD, Investigator

Nancy Aleid, Compliance Officer

---

**TOPIC I. Attendance by roll call:**

**CALL TO ORDER 8:03 AM**

A quorum of the Board was present, established by roll call. President Julie Lanza chaired the meeting and she explained that the Board of Pharmacy was recording the meeting.

Roll call attendance: J. Lanza, yes; C. Jean-Francois, yes; S. Hamilton, yes; C. Belisle, yes; R. Morrelli, yes; J. Rocchio, yes; J. Chin, yes; S. Cornacchio, yes; R. Lopez, yes; K. Thornell, yes. (D. Barnes present but audio problems; C. Belisle joins meeting at 8:50 AM)

---

**Delilah Barnes, RPh (Votes prior to 8:45 AM do not include D. Barnes due to audio problems which were resolved at 8:45 AM)**

---

**Topic II.**

**Approval of Agenda**

**TIME 8:03 AM**

**Agenda 12/17/21**

**DISCUSSION:**

Defer: none

Dave presents: Thank you to J. Lanza, outgoing president; Thank you to A. Stein, T. Fensky, and L. Giambarresi outgoing board members and Introduction of new board member: Rita Morrelli.

**ACTION:**

Motion by J. Chin, seconded by K. Thornell and voted unanimously by those present to approve the agenda with no noted change by roll call vote.

---

**Topic III**

**Approval of Board Minutes**

**TIME: 8:16 AM**

Minutes

1. Draft 12/3/21

Change: no changes

Action:

Motion by C. Jean-Francois seconded J. Chin and voted unanimously to approve the regular session minutes of 12/3/21 with noted change by roll call vote.

---

**C. Belisle joins the meeting at 8:50 AM**

---

**TOPIC IV**

**Flex**

1. **Pharmacy Issues related to Covid-19 and state of emergency. Time: 8:09 AM**

**Presented by: D. SENCABAUGH**

**Nothing to report.**

---

**2. Introduction of Rita Morelli**

**Time: 8:09 AM**

**Presented by:** D. SENCABAUGH

**Discussion:** Rita Morelli from MCPHS was welcomed as a new Board member in the academic seat.

**So noted.**

---

**3. A word of thanks to Andrew Stein**

**Time: 8:06 AM**

**Presented by:** D. SENCABAUGH

**Discussion:** Andrew Stein was thanked for his service as a Board member and was encouraged to reapply after the 3-year waiting period.

**So noted.**

---

**4. Comments to USP regarding proposed revisions to general chapters <795> and <797>**

**Time: 8:53 AM**

**Presented by:** W. FRISCH

**Discussion:** At the September 29th Board meeting, W. FRISCH provided information and highlights regarding USP's September 1, 2021, release of proposed revisions to USP <795>, Pharmaceutical Compounding of Nonsterile Preparations and USP <797>, Pharmaceutical Compounding of Sterile Preparations.

These two revised chapters had been the subject of appeals, primarily related to the beyond-use-date sections of the chapters. Due to the appeals, subsequent stakeholder engagement, and USP Expert Committee review, additional revisions were made to both draft chapters. There were minimal revisions to the prior (2019) drafts of USP <795> but there were more significant revisions to the prior draft of USP <797>.

USP has provided for a public comment period on the proposed changes until January 31, 2022. As with previous drafts of USP <795> and <797>, Board staff would like to submit comments on the Board's behalf. Many of the proposed comments address enhancing quality assurance standards in compounding pharmacies and are in accordance with the pharmacy reform legislation that was enacted in response to the compounding crisis.

C. BELISLE felt that limiting BUDs to 90-days may limit hospital options during drug shortages.

J. LANZA agreed with all the proposed comments and supports submission of the comments as written. She also noted that anyone can provide their own public comment to the USP Expert Committee.

S. AHMED supported all comments as written including limiting BUDs to 90 days especially given the compounding history in our state.

W. FRISCH stated that USP is unlikely to accept our recommendations but feels the Board should endorse a conservative approach with its comments.

**Action:** Motion by S. AHMED, seconded by C. BELISLE, and voted unanimously by those present, to provide the comments to the USP Expert Committee as written.

---

## 5. Election of Board Officers

Time: 9:04 AM

**Presented by:** D. SENCABAUGH

**Discussion:** The final vote for Board officers for 2022 was held.

**Action:** Vote by roll call by the majority of those present for C. BELISLE to be President Elect for 2022. (10 votes for C. Belisle; 2 votes for K. Thornell)

**Action:** Vote by roll call by the majority of those present for C. JEAN-FRANCOIS to be secretary for 2022. (9 votes for C. Jean-Francois; 3 votes for J; Chin)

---

## TOPIC V

### Applications

#### 1. Freedom Fertility Pharmacy DS89717 Waivers

Time: 8:17 AM

Recusals:

Presented by: Chris Meilinger and John Sisto

Discussion:

J. Sisto indicated that they are requesting to waive the requirement to acquire a DEA number from a transferring pharmacy. J. Sisto states that Freedom Fertility Pharmacy had a pharmacy that they used to transfer prescription fertility medications from in Texas, but that facility is front store only, and did not dispense, or have a DEA number. Board staff indicate that this waiver is specific to schedule 6 drugs and would be willing not collect the DEA number when they don't have a registration number but stated that they are required to adhere to other elements of the regulation that should be documented.

Motion was made by J. Rocchio to approve the waiver request; Seconded by S. Hamilton, then Board Members present voted unanimously by rollcall to approve motion.

---

**TOPIC VI****Policies****1. CriticalPoint courses for sterile compounding CE****Time: 8:24 AM****Presented by:** M. CHAN

**Discussion:** The CriticalPoint CE courses are used by many pharmacists to meet the sterile compounding CE requirement. Each sterile compounding course / module has several lessons within it, and it is the titles of the individual lessons that are reported to CPE Monitor, not the overall course titles. This makes it unclear that the lessons are specific to sterile compounding.

The April 1, 2021, list of CriticalPoint sterile compounding curriculum with objectives was provided to the Board members.

Board staff has contacted CriticalPoint and going forward they will meet the Board's compounding CE criteria but cannot change the currently available programs.

ACPE has also been contacted and they will consider adding a "tag" to denote whether a compounding CE is for sterile or non-sterile compounding.

**Action:** Motion by S. HAMILTON, seconded by J. CHIN, and voted unanimously by those present, to accept all programs on CriticalPoint's 2021-2022 Sterile Compounding eLearning Curriculum for Massachusetts sterile compounding CE credits.

---

**TOPIC VII****Petition for Waiver****1. Nnenna M. Iregbu PI162678****Waiver 247 CMR 3.01 (7)****TIME 8:34am****Represented by:** Self**Recusal:** Cornacchio, Rocchio

**Discussion:** N. IREGBU petitioned for a waiver of 247 CMR 3.01 (7) to retake her NAPLEX exam while supporting her family. She passed her MPJE exam but was unsuccessful in passing the NAPLEX postpartum. IREGBU plans to retake the NAPLEX shortly upon approval of her waiver request.

**Action:** A motion was made by S. Hamilton to approve the waiver of 247 CMR 3.01 (7) with an extension of 6 months; Seconded by K. Thornell, then Board Members present voted unanimously by rollcall to approve motion except S. Cornacchio and J. Rocchio who recused.

---

**TOPIC VIII****PTT License Extension Request****1. PTT04818****Mann, Penny (CVS)****TIME 8:39am****Represented by:** Self



**Recusal: Cornacchio, Rocchio**

Discussion: P. MANN petitioned for an extension of her pharmacy technician trainee license. She was previously a shift manager for Walgreens; however, due to a staffing shortage, she had limited time in the pharmacy. MANN recently began employment at CVS and was given the opportunity to continue training in the pharmacy as a pharmacy technician.

Action: A motion was made by J. Chin to extend the expiration date of P. Mann's pharmacy technician trainee license by one year; Seconded by C. Jean-Francois, then Board Members present voted unanimously by rollcall to approve motion except S. Cornacchio and J. Rocchio who recused.

---

**2. PTT05976 Delea, Daniel (CVS) TIME 8:44am**

**Represented by: Self**

**Recusal: Cornacchio, Rocchio**

Discussion: D. DELEA petitioned for an extension of his pharmacy technician trainee license. He was previously appointed as a shift supervisor at CVS. Due to operational issues, DELEA was not able to transition into the pharmacy prior to his license expiration. He was recently given the opportunity to begin training in the pharmacy as a pharmacy technician.

Action: A motion was made by J. Chin to extend the expiration date of D. Delea's pharmacy technician trainee license by one year; Seconded by C. Jean-Francois, then Board Members present voted unanimously by rollcall to approve motion except S. Cornacchio and J. Rocchio who recused.

---

**3. PTT08466 Colston, Sarah (CVS) TIME 8:47am**

**Represented by: Self**

**Recusal: Cornacchio, Rocchio**

Discussion: S. COLSTON petitioned for an extension of her pharmacy technician trainee license. Due to COVID restrictions, she needed to resign from her position at CVS to assist her son with online schooling. She is currently able to start working outside of the home again and was given the opportunity to continue training in the pharmacy as a pharmacy technician at CVS.

Action: A motion was made by C. Jean-Francois to extend the expiration date of S. Colston's pharmacy technician trainee license by one year; Seconded by S. Hamilton, then Board Members present voted unanimously by rollcall to approve motion except S. Cornacchio and J. Rocchio who recused.

---

**TOPIC IX**

**File Review**

Case #1/CAS-2021-0979

Time: 08:31 AM

SA-INV-18620

Onyeijen Mgbejume, PH237291

RECUSAL: NONE

DISCUSSION: C.MOGNI presented and summarized the investigative report that pertained to this matter.

- A NABP Clearinghouse Action Report was received of discipline by the CT Commission of Pharmacy on 2/9/2009 stating Pharmacist Mgbejume committed two prescription errors within a three-year period. He received a Letter of Reprimand and agreed to complete an online CE course related to prescription errors before 04/30/2009. Pharmacist Mgbejume's MA license expired 12/31/2018.
- In response, Pharmacist Mgbejume stated he obtained his MA license in 2016 due to the proximity of his residence in CT, but never practiced in MA and the license is currently expired. He completed the CEs on prescription errors in 2009. Currently he's not practicing. He learned from the experience and would continue to exercise caution when he decides to practice again.

Pharmacist Mgbejume holds 2 additional expired pharmacist licenses in ME and LA and 2 current pharmacist licenses in FL and TX.

ACTION: Motion by K. THORNELL, seconded by J. CHIN, and voted unanimously by those present, to CLOSE the matter (SA-INV-18620), No Discipline Warranted, Remediation Complete.

---

Case #2/CAS-2021-0777

PHA-2021-0074

CVS #166, DS3449

Time: 09:14 AM

RECUSAL: S. CORNACCHIO, and J. ROCCHIO recused and were not present for the discussion or vote in this matter.

DISCUSSION: C. MOGNI presented and summarized the investigative report that pertained to this matter.

- Inspectional deficiencies cited during an inspection on 8/11/21 for storage of an epinephrine auto-injector outside of the Pharmacy in an unsecured "immunization booth" in the front store.
- According to MOR Saengkheune, PI Sanchez-Reyes was on the second day of his APPE rotation on the day of inspection. PI Sanchez-Reyes was normally employed at CVS #153 in Worcester where he had been immunizing. MOR Saengkheune stated at the pharmacy all immunizers had been thoroughly coached to bring a small tray containing vaccine, supplies, and the epinephrine auto-injector to the immunization booth when administering vaccines then bring the tray back with them when returning to the Pharmacy. MOR Saengkheune indicated as PI Sanchez-Reyes was getting acclimated to the immunization workflow at the Pharmacy, she should have better monitored his technique and reviewed protocols, and not assumed that he knew, when returning to the Pharmacy, he was to bring back the tray including the epinephrine auto-injector. MOR Saengkheune informed PI Sanchez-Reyes of the process and that if he leaves the immunization booth for any reason, the epinephrine needs to be returned to the Pharmacy. She claimed PI Sanchez-Reyes reported that at CVS #153 they do not bring out the epinephrine auto-injector to the booth when administering vaccines to patients.
- PI Sanchez-Reyes stated on 8/11/21 he went to the restroom after administering immunizations which was when the deficiency was observed. The Investigator explained to him that epinephrine cannot be left unattended outside of the Pharmacy. PI Sanchez-Reyes was unaware that the epinephrine auto-injectors had to be carried with you each time when providing immunizations.
- MOR Saengkheune will ensure that all immunizing personnel will be oriented to workflow practices prior to using in the immunization booths. PI Sanchez-Reyes stated, "Since then, I am now aware of how important this situation is and what this means for my future in becoming a pharmacist. I will do all my best and follow all instructions, policy or standards that are implemented". A statement signed

and dated by the Pharmacy staff was submitted confirming all policies and procedures related to the CVS Pharmacy COVID-19 vaccination booths and COVID-19 immunizer programs were reviewed.

ACTION: Motion by S. HAMILTON, seconded by K. THORNELL, and voted unanimously by those present, to DISMISS the matter (PHA-2021-0074), No Discipline Warranted, Remediation Complete.

---

Case #3/CAS-2021-0778

PHA-2021-0075

CVS #657, DS89715

Time: 09:19 AM

RECUSAL: S. CORNACCHIO, and J. ROCCHIO recused and were not present for the discussion or vote in this matter.

DISCUSSION: C. MOGNI presented and summarized the investigative report that pertained to this matter.

- Inspectional deficiencies cited during an inspection (ISP-16591) on 8/11/21 for storage of epinephrine auto-injectors outside of the Pharmacy in unsecured “immunization booths” in the front store. According to the POC, the epinephrine auto-injectors were immediately returned to the Pharmacy when notified. Immunizers will bring epinephrine as required when administering vaccinations in designated areas and it will be stored in the Pharmacy when not actively immunizing.
- MOR Kazzaz and the Pharmacy staff provided a statement indicating that when the use of the immunization booths stopped earlier in the year, the team failed to ensure the epinephrine was returned to the Pharmacy on the final day of the vaccination clinics . Normally the immunizer would bring the carts back to the Pharmacy for restocking after each clinic to ensure the epinephrine was stored in the Pharmacy and was never left unattended. A list was provided of the dates the immunization booths were in use which indicated they were last used on 5/27/2021.
- MOR Kazzaz and the Pharmacy team provided a signed statement indicating they will ensure all prescription drugs, including epinephrine, are secured in the Pharmacy. A reminder note will be left in the immunizing basket containing the epinephrine to ensure its return to the Pharmacy which the staff will confirm. The booth will be checked every day at end of shift to ensure no epinephrine is left behind. A statement signed and dated by the Pharmacy staff was submitted confirming all policies and procedures related to the CVS Pharmacy COVID-19 vaccination booths and COVID-19 immunizer programs were reviewed.

ACTION: Motion by J. CHIN, seconded by C. JEAN-FRANCOIS, and voted unanimously by those present, to DISMISS the matter (PHA-2021-0075), No Discipline Warranted, Remediation.

---

Case #4/CAS-2021-0652

PHA-2021-0055

CVS #1803, DS89888

Time: 09:22 AM

RECUSAL: S. CORNACCHIO, and J. ROCCHIO recused and were not present for the discussion or vote in this matter.

DISCUSSION: J. TRIFONE presented and summarized the investigative report that pertained to this matter.

- RLCS #527 alprazolam 2mg tablets and #1046 alprazolam 1mg tablets discovered on 01/21/2021.
- Discovered by corporate CS monitoring

- Internal investigation initiated which lasted until the end of June 2021. (7 letters of continuation submitted)
- LP identified that a change in MOR inventory conducted on 10/23/20 was not transmitted to CVS corporate properly.
- No evidence of diversion; unable to determine the reason for the loss.
- Corrective action included review of LP policies with staff.

ACTION: Motion by J. CHIN, seconded by S. HAMILTON, and voted unanimously by those present, to REFER the matter (PHA-2021-0055), to the office of the prosecution for the issuance of an order to show cause and to authorize resolution of the matter by a consent agreement for STAYED PROBATION for a period of one year, with special terms to include conducting an exact count CS inventory for all scheduled 3-5 medications within 30 days, and a monthly exact count of all benzodiazepine products for 12 months, staff retraining in the areas of inventory management, prescription production, and waiting bin management within 30 days and increased store visits from the Pharmacy Supervisor or Loss Prevention at least once every 30 days to validate and sign off on the BOH report cover page.

---

Case #5/CAS-2021-0590  
PHA-2021-0048

CVS #354, DS3452

Time: 09:25 AM

RECUSAL: S. CORNACCHIO, and J. ROCCHIO recused and were not present for the discussion or vote in this matter.

DISCUSSION: J. TRIFONE presented and summarized the investigative report that pertained to this matter.

- During June 2021, CVS 365 submitted a final report of an unknown loss of 410 clonazepam 0.5mg discovered on January 11, 2021. CVS 365 explained that the losses were discovered during a reconciliation by loss prevention. An internal investigation was initiated at that time which lasted until approximately June 2021. The investigation ruled out diversion but was unable to determine a reason for the loss. Of note, MOR McCarthy opined that a stock bottle of 500 tablets was likely discarded which caused the loss.
- CA: CVS 365 indicated that loss prevention policies would be reviewed with pharmacy staff including “diligent inventory management and dispensing standards” to mitigate recurrence of a similar loss of controlled substance. In addition, positioning of surveillance cameras was optimized, and staff were required to perform double counts and initial those counts.

ACTION: Motion by J. CHIN, seconded by S. HAMILTON, and voted unanimously by those present, to REFER the matter (PHA-2021-0048), to the office of the prosecution for the issuance of an order to show cause and to authorize resolution of the matter by a consent agreement for STAYED PROBATION for a period of one year, with special terms to include conducting an exact count CS inventory for all scheduled 3-5 medications within 30 days, and a monthly exact count of all benzodiazepine products for 12 months, staff retraining in the areas of inventory management, prescription production, and waiting bin management within 30 days and increased store visits from the Pharmacy Supervisor or Loss Prevention at least once every 30 days to validate and sign off on the BOH report cover page.

---

Case #6/CAS-2021-0592  
PHA-2021-0046

CVS #2566, DS3086

Time: 09:28 AM

RECUSAL: S. CORNACCHIO, and J. ROCCHIO recused and were not present for the discussion or vote in this matter.

DISCUSSION: J. TRAN presented and summarized the investigative report that pertained to this matter.

- RLCS-#507 lorazepam 1mg tablets on or about March 16, 2021, and the investigation concluded was on June 16, 2021. Three letters of continuation were submitted during that time.
- The loss was discovered via corporate controlled substance monitoring and the investigation concluded that the reason for the loss was unknown.
- The video system was analyzed with no evidence of apparent diversion.
- MOR Balbino indicated that she coached the team to double count all controlled medication prior to dispensing. She also re-trained the pharmacists responsible for handling inventory counts on proper procedures to prevent inaccuracies. She reviewed all baseline loss prevention procedures with the entire staff, specifically those that prevent drug diversion.
- A retail compliance inspection (ISP-16734) conducted on August 25, 2021, was deemed satisfactory.

ACTION: Motion by S. HAMILTON, seconded by D. BARNES, and voted unanimously by those present, to REFER the matter (PHA-2021-0048), to the office of the prosecution for the issuance of an order to show cause and to authorize resolution of the matter by a consent agreement for STAYED PROBATION for a period of one year, with special terms to include conducting an exact count CS inventory for all scheduled 3-5 medications within 30 days, and a monthly exact count of all benzodiazepine products for 12 months, staff retraining in the areas of inventory management, prescription production, and waiting bin management within 30 days and increased store visits from the Pharmacy Supervisor or Loss Prevention at least once every 30 days to validate and sign off on the BOH report cover page.

---

**Topic X:** **Executive Session Call to Order:** **Time: 9:34 AM**  
By: J. Lanza

**Action:** A motion was made by to S. HAMILTON enter Executive Session; Seconded by C. Jean-Francois and Board Members present voted unanimously by roll call to approve motion. Roll call attendance: J. Lanza, yes; C. Jean-Francois, yes; S. Hamilton, yes; C. Belisle, yes; R. Morrelli, yes; J. Chin, yes; R. Lopez, yes; D. Barnes, yes; K. Thornell, yes; C. Belisle, yes.

---

**Topic XI:** **65C Sessions MGL c. 112 section 65C** **Time: 9:59 AM**

DISCUSSION: None

ACTION: President J. Lanza request a motion to enter 65C.

At 9:59 AM J. Chin, seconded by C. Jean-Francois and voted unanimously by all those present to enter 65C by roll call vote.

---

**S. Cornacchio leaves meeting at 10:07 AM**

**J. Rocchio leaves meeting at 10:07 AM**

**J. Trifone leaves meeting at 10:20 AM**

---

**Topic XII**

**ADJOURNMENT OF MEETING**

**TIME: 10:25 AM**

ACTION: Motion by C. Jean-Francois seconded by C. Belisle and voted unanimously by those present, to adjourn from General Session by roll call vote.

---

EXHIBITS USED DURING THE OPEN SESSION OF THE MEETING

1. Draft Agenda of the 12/17/21 General Session
2. Draft Minutes of the 12/3/21 Meeting
3. Applications: Freedom Fertility Pharmacy Ds89717 Waivers
4. Nnenna M. Iregbu PI162678 Petition for Waiver
5. PTT04818 Mann, Penny PTT Extension
6. PTT05976 Delea, Daniel PTT Extension
7. PTT08466 Colston, Sarah PTT Extension
8. CAS-2021-0979 SA-INV-18620 Onyeijen Mgbejume, PH237291
9. CAS-2012-0777 PHA-2021-0074 CVS #166, DS3449
10. CAS-2021-0778 PHA-2021-0075 CVS #657, DS89715
11. CAS-2021-0652 PHA-2021-0055 CVS #1803, DS8988
12. CAS-2021-0590 PHA-2021--0048 CVS #365, DS3452
13. CAS-2021-0592 PHA-2021-0046 CVS #2566, DS3086

Respectfully Submitted,  
Carly Jean-Francois, NP, Secretary